Daraxonrasib cleared both primary endpoints in a phase 3 trial for previously treated metastatic pancreatic cancer, Revolution Medicines reported April 13. The pan-RAS inhibitor hit overall survival and progression-free survival targets in patients with RAS G12 mutations. In the overall study population, median OS was 13.2 months versus 6.7 months for standard chemotherapy.
The late-stage study enrolled patients with metastatic pancreatic ductal adenocarcinoma whose prior treatment had failed. Revolution confirmed the trial also hit key secondary endpoints but hasn’t released PFS numbers, reserving the full dataset for the American Society of Clinical Oncology meeting in late May 2026.
Revolution’s next step is a regulatory submission package using the FDA’s national priority voucher scheme. Pancreatic cancer is the most RAS-addicted of all major cancers, with RAS mutations in over 90% of cases, and standard immunotherapy largely doesn’t work there. That gap is why Evaluate last month named daraxonrasib the most valuable orphan drug in development across biopharma, projecting $4 billion in annual sales by 2032.
Revolution already converted that valuation into cash, pulling in up to $2 billion from Royalty Pharma in exchange for a share of future profits if daraxonrasib reaches market.
Competition is forming. In January, Immuneering reported a 64% overall survival rate at 12 months for its MEK inhibitor atebimetinib in first-line PDAC patients, citing safety and tolerability as potential edges over daraxonrasib.
Revolution is also running a first-line PDAC phase 3 trial of daraxonrasib and has zoldonrasib in phase 3 for RAS G12D-mutant PDAC. Full data at ASCO, May 2026.
Sarah Chen